Argentina Cancer Research

Century of Research Excellence & Latin America's Proton Therapy Pioneer

100+

Years Research Excellence

Since 1922

1st

Proton Therapy in LATAM

Opened 2023

150%

Research Investment Growth

2020-2024

Major Research Breakthroughs

100+ Years of Cancer Research Excellence (Instituto Roffo, 1922)

1922-Present

Argentina's Instituto de Oncología Ángel H. Roffo, founded in 1922, is one of Latin America's oldest cancer research institutions, with a century of pioneering discoveries.

Instituto Roffo, University of Buenos Aires

Impact:

A century of training Latin America's oncology leaders

First Proton Therapy Center in Latin America

2023

Argentina opened Latin America's first proton therapy center in 2023, offering ultra-precise radiation treatment that spares healthy tissue.

Buenos Aires Proton Therapy Center

Impact:

Bringing advanced radiation technology to South America

150% Increase in Cancer Research Investment

2020-2024

Argentina increased cancer research funding by 150% from 2020-2024, fueling breakthroughs in immunotherapy and precision medicine.

Argentine Ministry of Science

Impact:

Accelerating Argentina's cancer research capabilities

CAR-T Therapy Development Partnership

2023-2024

Argentina partnered with Brazil and international biotech companies to develop and manufacture CAR-T therapies for South America.

Instituto Alexander Fleming, Fundación Sales

Impact:

Making advanced immunotherapy accessible regionally

Pediatric Cancer Treatment Excellence

Ongoing

Argentina's Hospital Garrahan is recognized as one of Latin America's top pediatric cancer centers, achieving survival rates comparable to developed nations.

Hospital Garrahan

Impact:

Saving children's lives with world-class pediatric oncology

Genetic Cancer Research in Latino Populations

2022-2024

Argentine researchers identified genetic variants unique to Latin American populations that influence cancer risk and treatment response.

CONICET (National Scientific Research Council)

Impact:

Enabling personalized cancer treatment for South Americans

Leading Research Institutions

Instituto de Oncología Ángel H. Roffo

Buenos Aires

Founded 1922. Latin America's oldest cancer research institute. Leading research in cancer biology, immunotherapy, and clinical trials.

Key Specialties:

Cancer Biology

Immunotherapy

Clinical Trials

Radiation Oncology

Instituto Alexander Fleming

Buenos Aires

Premier private cancer hospital. Pioneer in CAR-T therapy development and precision medicine for South America.

Key Specialties:

CAR-T Therapy

Precision Medicine

Breast Cancer

Lung Cancer

Hospital Garrahan

Buenos Aires

Top pediatric hospital in Latin America. Leading pediatric oncology center achieving world-class childhood cancer survival rates.

Key Specialties:

Pediatric Oncology

Leukemia

Brain Tumors

Bone Marrow Transplants

Active Clinical Trials in Argentina

Argentina welcomes international patients to cutting-edge clinical trials

CAR-T for B-Cell Lymphoma (Argentina-Brazil Partnership)

Phase 2

Testing South American-manufactured CAR-T cells for relapsed/refractory B-cell lymphomas.

Instituto Alexander Fleming

Active recruitment

Proton Therapy for Pediatric Cancers

Treatment Program

Advanced proton beam therapy for childhood brain tumors, sarcomas, and other cancers requiring precise radiation.

Buenos Aires Proton Therapy Center

Accepting patients

Precision Medicine for Latino Populations

Phase 2

Tailoring cancer treatments based on genetic variants specific to Latin American populations.

Instituto Roffo, CONICET

Active recruitment

Want to learn about more Argentine clinical trials? Search our database or contact our team.

Clinical Trials in Argentina

Registry-listed trials for Argentina currently tracked in our database, sourced from public trial registries.

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With or Without Bevacizumab in Comparison to Active Observation With or Without Bevacizumab as Maintenance Treatment in Participants With Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer

Phase III

Not yet recruiting

NCT07694427

View registry record

A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer

Phase III

Recruiting

NCT07541170

View registry record

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase II

Recruiting

NCT07680764

Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

View registry record

79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Phase II

Recruiting

NCT07589634

Multiple Myeloma

View registry record

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

Phase III

Recruiting

NCT07286331

Neoplasms, Endometrial

View registry record

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

Phase II

Recruiting

NCT07413939

View registry record

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Phase II

Recruiting

NCT06972615

View registry record

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Phase II

Recruiting

NCT06972615

View registry record

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Phase II

Recruiting

NCT06972615

View registry record

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Phase II

Recruiting

NCT06972615

View registry record

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Phase II

Recruiting

NCT06972615

View registry record

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

Phase II

Recruiting

NCT07413939

HER2-positive Breast Cancer

View registry record

Argentina Cancer Research

100+ Years of Cancer Research Excellence (Instituto Roffo, 1922)

First Proton Therapy Center in Latin America

150% Increase in Cancer Research Investment

CAR-T Therapy Development Partnership

Pediatric Cancer Treatment Excellence

Genetic Cancer Research in Latino Populations

Instituto de Oncología Ángel H. Roffo

Instituto Alexander Fleming

Hospital Garrahan

CAR-T for B-Cell Lymphoma (Argentina-Brazil Partnership)

Proton Therapy for Pediatric Cancers

Precision Medicine for Latino Populations

A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer

79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy

Latest Research Ecosystem Developments

Active Participation in International Clinical Trials

National Cancer Institute (NCI) Coordination

Regional Leadership in Clinical Research

Ongoing Clinical Trial Infrastructure